Commentary: Autoimmune diseases in patients with myotonic dystrophy type 2

被引：1
|
作者：
Damen, Manon J. [1 ,2 ]
den Broeder, Alfons A. [3 ]
Voermans, Nicol C. [1 ]
Tieleman, Alide A. [1 ]
机构：
[1] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Neurol, Med Ctr, Nijmegen, Netherlands
[2] Med Spectrum Twente, Dept Neurol, Enschede, Netherlands
[3] Sint Maartensklin, Dept Rheumatol, Nijmegen, Netherlands
来源：
FRONTIERS IN NEUROLOGY | 2022年 / 13卷
关键词：
T cell immunity; B cell immunity; interleukin 6 (IL-6); interleukin 12 (IL-12); Th1; CCHC-Type Zinc Finger Nucleic Acid Binding Protein (CNBP); myotonic dystrophy type 2 (DM2); autoimmune diseases (AIDs);
D O I：
10.3389/fneur.2022.1041437
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Myotonic dystrophy type 2 and related myotonic disorders
    Giovanni Meola
    Richard T. Moxley
    Journal of Neurology, 2004, 251 : 1173 - 1182
  • [22] Myotonic dystrophy type 2 and related myotonic disorders
    Meola, G
    Moxley, RT
    JOURNAL OF NEUROLOGY, 2004, 251 (10) : 1173 - 1182
  • [23] Cognitive function assessment in patients with myotonic dystrophy type 2
    Peric, Stojan
    Gunjic, Ilija
    Salak-Djokic, Biljana
    Delic, Neda
    Bozovic, Ivo
    Basta, Ivana
    Rakocevic-Stojanovic, Vidosava
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [24] Current Treatment Options for Patients with Myotonic Dystrophy Type 2
    Montagnese, Federica
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2021, 23 (09)
  • [25] Muscle pathology in 57 patients with myotonic dystrophy type 2
    Schoser, BGH
    Schneider-Gold, C
    Kress, W
    Goebel, HH
    Reilich, P
    Koch, MC
    Pongratz, DE
    Toyka, KV
    Lochmüller, H
    Ricker, K
    MUSCLE & NERVE, 2004, 29 (02) : 275 - 281
  • [26] Myotonic dystrophy type 2: clinical characteristics of 23 patients
    Lusakowska, A.
    Sulek, A.
    Krysa, W.
    Nadaj-Pakleza, A.
    Szmidt-Salkowska, E.
    Pruszczyk, P.
    Kaminska, A. M.
    JOURNAL OF NEUROLOGY, 2007, 254 : 153 - 153
  • [27] Current Treatment Options for Patients with Myotonic Dystrophy Type 2
    Federica Montagnese
    Current Treatment Options in Neurology, 2021, 23
  • [28] Dysphagia in Myotonic Dystrophy type 2
    Tieleman, A. A.
    van Vliet, J.
    Knuijt, S.
    de Swart, B. J. M.
    Ensink, R.
    van Engelen, B. G. M.
    NEUROMUSCULAR DISORDERS, 2008, 18 (9-10) : 796 - 797
  • [29] Pain in patients with myotonic dystrophy: Comparison between type 1 and type 2
    Vohanka, S.
    Parmova, O.
    Strenkova, J.
    NEUROMUSCULAR DISORDERS, 2013, 23 (9-10) : 834 - 835
  • [30] Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.
    Ranum L.P.
    Day J.W.
    Current Neurology and Neuroscience Reports, 2002, 2 (5) : 465 - 470
12345